Direct Comparison on Stomach Safety
Celecoxib, a COX-2 selective NSAID, causes fewer gastrointestinal (GI) ulcers and bleeding events than naproxen, a non-selective NSAID, in most clinical studies. This stems from celecoxib's reduced inhibition of COX-1, the enzyme protecting the stomach lining.[1][2]
Key Clinical Evidence
The PRECISION trial (2016), involving over 24,000 arthritis patients at high cardiovascular risk, found celecoxib (100mg twice daily) linked to a 48% lower risk of GI events like ulcers and perforations compared to naproxen (375-500mg twice daily), even when naproxen was paired with a proton pump inhibitor.[1] Meta-analyses confirm this: COX-2 inhibitors reduce endoscopic ulcers by 50-70% versus non-selective NSAIDs like naproxen.[2][3]
Why the Stomach Difference Matters
Naproxen damages the stomach more because it blocks both COX-1 and COX-2 equally, thinning protective mucus and increasing ulcer risk—especially in older adults or those on aspirin/steroids. Celecoxib spares COX-1, cutting this risk, though it still carries some GI warnings.[4]
Does Adding Protection Equalize Them?
Naproxen plus a PPI (like omeprazole) narrows the gap but doesn't fully match celecoxib's profile. PRECISION showed celecoxib superior even against protected naproxen, with fewer treatment discontinuations due to GI issues.[1] Guidelines like those from the American College of Rheumatology recommend COX-2 options first for high GI-risk patients.[5]
Cardiovascular Trade-Offs
Celecoxib may raise heart attack/stroke risk slightly less than naproxen in some data (PRECISION: 20-30% lower CV events), but FDA black-box warnings apply to all NSAIDs for CV/GI risks.[1][6] Stomach safety favors celecoxib, but CV history tips decisions toward naproxen in low-GI-risk cases.
Who Should Pick What?